Hof H
Institute of Medical Microbiology and Hygiene, University of Heidelberg, FRG.
J Antimicrob Chemother. 1990 Jan;25(1):121-6. doi: 10.1093/jac/25.1.121.
CI 934, a new quinolone, is only marginally more active in vitro against Listeria monocytogenes and other Listeria spp. than ciprofloxacin. A bactericidal effect is seen only after several hours of incubation. However, mice infected with a virulent strain of L. monocytogenes were protected by parenteral treatment with CI 934. With a dosage of 2 x 2 mg CI 934 per day for three days almost complete remission could be achieved. These results are somewhat better than those obtained in previous experiments with other antibiotics.
CI 934是一种新型喹诺酮类药物，其体外抗单核细胞增生李斯特菌及其他李斯特菌属的活性仅略高于环丙沙星。仅在孵育数小时后才可见杀菌作用。然而，感染了单核细胞增生李斯特菌强毒株的小鼠经CI 934非肠道给药治疗后受到了保护。每天剂量为2×2mg CI 934，连用三天，几乎可实现完全缓解。这些结果比之前使用其他抗生素进行的实验所获得的结果要好一些。
